ProCE Banner Activity

Future Treatment of Obesity: GLP-1 Receptor Agonists

Clinical Thought

GLP-1 receptor agonists have been used successfully for glycemic control and weight loss in patients with type 2 diabetes. Here’s my take on how we can also use them for people with obesity.

Released: February 09, 2023

Expiration: February 08, 2024

No longer available for credit.

Share

Faculty

Caroline Apovian

Caroline Apovian, MD

Member of the Faculty
Endocrinology, Diabetes, and Hypertension
Harvard Medical School
Co-Director
Center for Weight Management and Wellness
Brigham and Womens Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Caroline Apovian, MD

Member of the Faculty
Endocrinology, Diabetes, and Hypertension
Harvard Medical School
Co-Director
Center for Weight Management and Wellness
Brigham and Womens Hospital
Boston, Massachusetts

Caroline Apovian, MD: consultant/advisor/speaker: Abbott Nutrition, Allergan, Inc., Altimmune, Inc., Cowen and Company, LLC, Curavit Clinical Research, Currax Pharmaceuticals, LLC, EnteroMedics, EPG Communication Holdings Ltd., Gelesis, Srl., Jazz Pharmaceuticals, Inc., L-Nutra, Inc., NeuroBo Pharmaceuticals, Inc., Novo Nordisk, Inc., Pain Script Corporation, Pursuit By You, Real Appeal, Riverview School, Rhythm Pharmaceuticals, Roman Health Ventures, Inc., Scientific Intake Ltd. Co., Tivity Health, Inc., Xeno Biosciences, and Zafgen Inc.; research: GI Dynamics, Inc., NIH, Novo Nordisk, PCORI.